Big pharma, Partnering, Pharma

Gilead and Mylan expand Sovaldi pact

Posted on 27 January 2015

Tags: , , ,

Mylan Laboratories is expanding its hepatitis C licensing agreement with Gilead Sciences to include the non-exclusive rights to manufacture and distribute the investigational NS5A inhibitor GS-5816 and single tablet regimen of sofosbuvir(Sovaldi)/GS-5816, once approved, in 91 developing countries.

The single tablet regimen is being evaluated in Phase 3 clinical studies for the treatment of all six genotypes of hepatitis C.

Searching for more deal information? Current Partnering offers the following options:

  • CP Reports | Browse titles | Over 200 report titles that focus upon different deal types from licensing, co-promotion to distribution, biomarkers to drug delivery, oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
  • Current Agreements | Login | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities
  • CP Knowledge Centre | Login | Find out more | Provides you with an all-in-one intelligence package that allows you to simultaneously access our CP reports, CP Insight and Current Agreements deal and alliances database, at the same time

 

This agreement is in addition to the licensing and technology transfer agreement that Mylan entered into with Gilead in September 2014, which grants Mylan the non-exclusive rights to manufacture and distribute sofosbuvir and ledipasvir/sofosbuvir in 91 developing countries.

Mylan also partners with Gilead on expanding access to high quality, affordable antiretrovirals for the treatment of HIV/AIDS in India and other developing countries.

For further deal information visit Current Agreements (subscription required)

Related

Scorecard: Top partnering deals by value in 2014

View: Top pharmaceutical companies

View: Top biotech companies

Reports: Browse our extensive deal making report portfolio

Print Friendly, PDF & Email

Leave a Reply